苯达莫司汀淋巴细胞清除是氟达拉滨联合环磷酰胺淋巴细胞清除用于侵袭性B细胞淋巴瘤阿基仑赛治疗的良好耐受替代方案
该回顾性研究比较了苯达莫司汀(n=27)与氟达拉滨/环磷酰胺(Flu/Cy,n=42)淋巴细胞清除后行阿基仑赛(axi-cel)治疗的复发/难治侵袭性B细胞淋巴瘤患者。两组疗效相当,苯达莫司汀组任何级别ICANS更低,且更多患者可在门诊接受治疗且不增加毒性、住院时间更短。
要点
- 苯达莫司汀组与Flu/Cy组最佳总缓解率分别为77.8%与81.0%,完全缓解率分别为48.1%与50.0%。
- 苯达莫司汀组任何级别ICANS发生率为30%,低于Flu/Cy组的55%。
- 苯达莫司汀组3级及以上中性粒细胞减少发生率为68%,低于Flu/Cy组的100%。
核心结论
- 与Flu/Cy淋巴细胞清除相比,苯达莫司汀淋巴细胞清除后行axi-cel治疗观察到相当的疗效,且任何级别ICANS更低。
研究设计与样本
- 回顾性评估在本机构接受axi-cel治疗前接受苯达莫司汀(n=27)或Flu/Cy(n=42)淋巴细胞清除的复发/难治侵袭性B细胞淋巴瘤患者。
主要发现
- 从淋巴细胞清除前到axi-cel输注时绝对淋巴细胞计数中位变化:苯达莫司汀组为-0.6×10^9/L,Flu/Cy组为-0.7×10^9/L。
- 最佳总缓解率/完全缓解率:苯达莫司汀组77.8%(95%CI:57.7%-91.4%)/48.1%(95%CI:28.7%-68.1%),Flu/Cy组81.0%(95%CI:65.9%-91.4%)/50.0%(95%CI:34.2%-65.8%)。
- 6个月无进展生存率:苯达莫司汀组43.8%(95%CI:24.7%-61.3%),Flu/Cy组55.6%(95%CI:39.0%-69.3%);6个月总生存率分别为81.5%(95%CI:61.1%-91.8%)和90.4%(95%CI:76.4%-96.3%)。
- 调整基线既往治疗数和难治性疾病后,苯达莫司汀组与Flu/Cy组相比,进展/复发/死亡风险无增加(aHR:1.4 [95%CI:0.7-2.8];p=.32),死亡风险无增加(aHR:1.6 [95%CI:0.5-5.6];p=.46)。
- 任何级别/3级及以上CRS:苯达莫司汀组89%/3.7%,Flu/Cy组86%/4.8%;任何级别/3级及以上ICANS:苯达莫司汀组30%/19%,Flu/Cy组55%/31%。
临床怎么用
- 作者观察到苯达莫司汀淋巴细胞清除后行axi-cel治疗与Flu/Cy相比疗效相当且任何级别ICANS更低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fludarabine/cyclophosphamide (Flu/Cy) is established for lymphodepletion (LD) prior to standard-of-care CAR T-cell therapy for lymphoma. There is ongoing need to test alternative LD regimens to preserve efficacy, improve safety, and address challenges including the recent national fludarabine shortage. We retrospectively evaluated outcomes among patients with relapsed/refractory aggressive B-cell lymphoma who received bendamustine (n = 27) or Flu/Cy (n = 42) LD before axicabtagene ciloleucel (axi-cel) at our institution. The median change in absolute lymphocyte count from pre-LD to time of axi-cel infusion was -0.6×109 /L in bendamustine cohort and -0.7×109 /L in Flu/Cy cohort. The best overall response/complete response rates were 77.8% (95% CI: 57.7%-91.4%)/48.1% (95% CI: 28.7%-68.1%) among bendamustine cohort and 81.0% (95% CI: 65.9%-91.4%)/50.0% (95% CI: 34.2%-65.8%) among Flu/Cy cohort. Six-month progression-free survival were 43.8% (95% CI: 24.7%-61.3%) and 55.6% (95% CI: 39.0%-69.3%) in bendamustine and Flu/Cy cohorts, while 6-month overall survival were 81.5% (95% CI: 61.1%-91.8%) and 90.4% (95% CI: 76.4%-96.3%), respectively. Relative to Flu/Cy-treated patients, bendamustine-treated patients did not show an increase in hazards associated with experiencing progression/relapse/death (aHR:1.4 [95% CI: 0.7-2.8]; p = .32) or death (aHR:1.6 [95% CI: 0.5-5.6]; p = .46), after adjusting for baseline number of prior therapies and refractory disease. Any grade/grade ≥3 CRS were observed in 89%/3.7% and 86%/4.8% among bendamustine and Flu/Cy cohorts, while any grade ICANS/grade ≥3 ICANS were observed in 30%/19% and 55%/31% respectively. While more Flu/Cy-treated patients experienced grade ≥3 neutropenia compared with bendamustine-treated patients (100% vs. 68%), grade ≥3 infectious complications were comparable (24% vs. 19% respectively). More patients received bendamustine LD and axi-cel as outpatient than Flu/Cy cohort, without increased toxicities and with shorter median inpatient stays. In conclusion, we observed comparable efficacy and lower any grade ICANS among patients receiving bendamustine relative to Flu/Cy LD, followed by axi-cel.
引用
- Ong SY, Pak S, Mei M, et al. Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma. Am J Hematol. 2023. PMID: 37668287. doi:10.1002/ajh.27069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。